A Novel Microfluidic Point-of-Care Biosensor System on Printed Circuit Board for Cytokine Detection.
A Novel Microfluidic Point-of-Care Biosensor System on Printed Circuit Board for Cytokine Detection.
复制标题
DOI：
10.3390/s18114011
复制
发表时间：
2018-11-17
期刊：
影响因子：
--
通讯作者：
Prodromakis T
中科院分区：
文献类型：
--
作者：
Evans D;Papadimitriou KI;Vasilakis N;Pantelidis P;Kelleher P;Morgan H;Prodromakis T
在过去几十年里，由于快速有效地检测疾病和降低医疗成本的压力，护理点 (PoC) 诊断一直是大量研究的主题。在此，我们展示了一种新型的、完全集成的微流体安培酶联免疫吸附测定（ELISA）原型，使用商业干扰素γ释放测定（IGRA）作为模型抗体结合系统。微流体分析化学经过精心设计，可在基于印刷电路板 (PCB) 的生物传感器系统的分析单元内的镀金电极上进行。该测定单元与电化学报告单元相连，该单元包括微流体结构、Au 工作电极和对电极以及 Ag/AgCl 参比电极，所有这些均通过标准商业 PCB 制造工艺专门制造。分析化学已针对微流体扩散动力学进行了优化，可在连续流动下发挥作用。我们参考生物采样和缓冲液成分来表征所开发平台的电极完整性，随后我们展示了 H2O2 消耗的浓度依赖性测量，并通过现有 FDA 验证的 ELISA 试剂盒解决了这一问题。最后，我们验证了缓冲液和血清中的检测技术，并证明了与高端商业系统相当的检测限，并添加了能够在大约八分钟内返回诊断分析的完整微流体检测架构。
Point of Care (PoC) diagnostics have been the subject of considerable research over the last few decades driven by the pressure to detect diseases quickly and effectively and reduce healthcare costs. Herein, we demonstrate a novel, fully integrated, microfluidic amperometric enzyme-linked immunosorbent assay (ELISA) prototype using a commercial interferon gamma release assay (IGRA) as a model antibody binding system. Microfluidic assay chemistry was engineered to take place on Au-plated electrodes within an assay cell on a printed circuit board (PCB)-based biosensor system. The assay cell is linked to an electrochemical reporter cell comprising microfluidic architecture, Au working and counter electrodes and a Ag/AgCl reference electrode, all manufactured exclusively via standard commercial PCB fabrication processes. Assay chemistry has been optimised for microfluidic diffusion kinetics to function under continual flow. We characterised the electrode integrity of the developed platforms with reference to biological sampling and buffer composition and subsequently we demonstrated concentration-dependent measurements of H2O2 depletion as resolved by existing FDA-validated ELISA kits. Finally, we validated the assay technology in both buffer and serum and demonstrate limits of detection comparable to high-end commercial systems with the addition of full microfluidic assay architecture capable of returning diagnostic analyses in approximately eight minutes.
登录
查看更多内容
结核病诊断的进展：XPERT MTB/RIF分析和未来的预期测试。
DOI：
10.1016/s1473-3099(13)70008-2
发表时间：
2013-04
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Lawn SD;Mwaba P;Bates M;Piatek A;Alexander H;Marais BJ;Cuevas LE;McHugh TD;Zijenah L;Kapata N;Abubakar I;McNerney R;Hoelscher M;Memish ZA;Migliori GB;Kim P;Maeurer M;Schito M;Zumla A
通讯作者：
Zumla A
影响因子：
8.4
作者：
Jiang, Jing;Wang, Xinhao;Liu, Gang Logan
通讯作者：
Liu, Gang Logan
基于氧化石墨烯的可回收体内装置用于电流监测炎症小鼠的干扰素-γ
影响因子：
9.5
作者：
Cao, Chaomin;Jin, Ronghua;Liu, Guozhen
通讯作者：
Liu, Guozhen
影响因子：
12.6
作者：
Jolly, Pawan;Rainbow, Joshua;Moschou, Despina
通讯作者：
Moschou, Despina
影响因子：
8.9
作者：
Ding, Shaowei;Mosher, Curtis;Claussen, Jonathan C.
通讯作者：
Claussen, Jonathan C.